MedTrace Logo

Enhancement of a Psychotherapeutic Intervention Through Transcranial Direct Current Stimulation (tDCS)

NCT04096625 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-09-28

No results posted yet for this study

Summary

Transcranial Direct Current Stimulation (tDCS), is a neuromodulatory technique, that is safe, well-tolerated, easy to administer and fairly inexpensive. Results from tDCS trials involving participants with several neuropsychiatric disorders, including major depression, bipolar disorder, schizophrenia and substance use disorder are encouraging. The clinical effects of tDCS are broad; the underlying condition, the areas stimulated together with the type and duration of stimulation are important factors. In patients with neuropsychiatric conditions, a reduction of symptoms, an enhancement of neurocognitive functions together with an overall improvement in functionality and wellbeing have been consistently reported. These effects emerge during the stimulation period, in the weeks after stimulation, the effects seem to peak and consolidate further. tDCS appears to enhance the effects of other interventions as well; however, to date, there have been no studies into the effects of using tDCS as an add-on intervention to psychotherapy on symptoms and wellbeing

Conditions

  • Psychiatric Disorder

Interventions

DEVICE

Active tDCS

Active tDCS will be delivered at 2mA for 20 minutes.

BEHAVIORAL

Assertiveness Training Program (ATP)

The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.

DEVICE

Sham tDCS

Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).

Sponsors & Collaborators

  • Psychiatric University Hospital, Zurich

    lead OTHER

Principal Investigators

  • Stephan T. Egger, MD · Psychiatric University Hospital of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-11-30
Completion
2025-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04096625 on ClinicalTrials.gov